Research
Hormonal
Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome and a cardiovascular risk factor, driven by lipotoxicity rather than triglycerides alone.
Treating NAFLD requires addressing the underlying metabolic dysfunction and reducing toxic lipid metabolites, not just lowering liver fat content.
GoodSupportsHIGH confidence
In the current view, TGs per se do not cause inflammation, but rather they would promote the generation of toxic lipid metabolites, mainly oxidized LDLs, resulting in oxidative stress.
Why this rating
Supported by multiple studies cited.
Source
Impact of different ectopic fat depots on cardiovascular and metabolic diseases
Daniele Ferrara et al. · Journal of Cellular Physiology · 2019
DOI 10.1002/jcp.28821
narrative_reviewCited 184×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Ectopic fat accumulation in organs such as the heart, liver, and pancreas is a primary driver of cardiometabolic disease and insulin resistance, often posing a higher risk than classical metrics like BMI.Good
- Epicardial adipose tissue (EAT) and myocardial steatosis contribute to cardiac dysfunction and atrial fibrillation through lipotoxicity, involving the accumulation of diacylglycerols and ceramides.Good
- Weight loss, particularly through bariatric surgery or lifestyle interventions, significantly reduces ectopic fat in the liver, pancreas, and heart, improving metabolic health.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →